Authors
Zhixiong Lin, Jie Ma, Yonggao Mou, Songtao Qi, Xuejun Yang, Jianguo Xu, Yi Lin, Yi Liu, Chuan Zhao, Wenhao An, Feng Wan, Songbai Gui, Gao Zeng, Ping Liang, Yiguang Chen, Yang Zhao, Mingwang Zhu, Chunde Li, Jian Gong, Yongxin Wang, Yaming Wang, Jie Zhao, Yan Ju, Ye Song, Xiaosheng He, Xingfu Wang, Xiaofang Yan, Xianxin Qiu, Hao Li, Yang Wang, Rong Zhang, Jie Gong, Xueling Qi, Ming Ge, Julei Wang, Qingguo Li, Jun Fan, Xiaobing Jiang, Shibin Sun, Wenzhong Mei, Zheming Fang, Song Han, Bo Zhang, Pediatric Neurosurgery Group of the Neurosurgery Section of the Chinese Medical Association, the Neurological Tumor Expert Committee of the Chinese Society of Clinical Oncology and the Neuro-Oncology Committee of the Chinese Anti-Cancer Association
Published in
Cancer letters. Pages 218784. Aug 18, 2026. Epub Aug 18, 2026.
Abstract
This guideline was developed under the auspices of the Pediatric Neurosurgery Group of the Neurosurgery Branch of the Chinese Medical Association, the Neuro-oncology Expert Committee of the Chinese Society of Clinical Oncology, and the Neuro-oncology Professional Committee of the China Anti-Cancer Association. Craniopharyngioma is the most common tumor in the sellar turcica region among children, with the majority being adamantinomatous craniopharyngioma (ACP) and a smaller proportion being papillary craniopharyngioma (PCP). Management of craniopharyngioma involves not only tumor control but also the treatment of tumor-related hypothalamic dysfunction and pituitary endocrine disorders. To standardize the diagnosis and management of pediatric craniopharyngioma, this guideline incorporates evidence from 398 literature references. It provides recommendations on diagnostic evaluation, surgical strategies, radiotherapy principles, prognostic assessment, follow-up and long-term management, and targeted therapy. This guideline is intended to serve as a reference for healthcare professionals engaged in pediatric neuro-oncology. Recommendations were developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, taking into account the quality of evidence, clinical applicability, and expert consensus. Key recommendations are supported by explanatory rationale. The guideline were reviewed and approved by 35 multidisciplinary experts and 6 external reviewers, followed by formal voting on each recommendation. For areas lacking high-quality evidences, future well-designed clinical trials are recommended to validate and update these recommendations.
PMID:
42612900
Bibliographic data and abstract were imported from PubMed on 19 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 18
- Comments 0